Deep vein thrombosis screening: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 2: | Line 2: | ||
In-spite of identifying patients at increased risk of VTE, there is no clear clinical value for screening, the following reason explains | In-spite of identifying patients at increased risk of VTE, there is no clear clinical value for screening, the following reason explains | ||
*The strongest risk factor for VTE recurrence is the prior VTE event itself. | *The strongest risk factor for VTE recurrence is the prior VTE event itself. | ||
*After discontinuation of warfarin in VTE patients, especially where the cause was unknown, | *After discontinuation of warfarin in VTE patients, especially where the cause was unknown, there are still at high risk of recurrence. irrespective of the presence of inherited thrombophilia. | ||
*Anticoagulant prophylaxis is rarely recommended in asymptomatic affected family members outside of high risk situations. | *Anticoagulant prophylaxis is rarely recommended in asymptomatic affected family members outside of high risk situations. | ||
Revision as of 14:40, 24 August 2011
Value of screening
In-spite of identifying patients at increased risk of VTE, there is no clear clinical value for screening, the following reason explains
- The strongest risk factor for VTE recurrence is the prior VTE event itself.
- After discontinuation of warfarin in VTE patients, especially where the cause was unknown, there are still at high risk of recurrence. irrespective of the presence of inherited thrombophilia.
- Anticoagulant prophylaxis is rarely recommended in asymptomatic affected family members outside of high risk situations.